6160:HKEXBeOne Medicines Ltd. Analysis

BeOne Medicines posted a **34% year‑over‑year revenue jump** in Q1 2026, driven by a **38% surge in BRUKINSA sales**, and management lifted its full‑year guidance, underscoring the strength of its oncology franchise. The company’s **gross margin of 88%** and **operating margin of 16.5%** reflect a highly profitable business model, while cash reserves of **HK$4.8 bn** comfortably exceed its debt of **HK$1.1 bn**. However, the stock trades at a trailing P/E of 59.5 versus an industry average of 24.8**, and a DCF‑derived fair value of **HK$27**, implying a **~60% overvaluation** at the current price of **HK$158.9**.
Technically, the share price sits below its 20‑, 50‑ and 200‑day SMAs, the MACD is in a bearish crossover, and the RSI at 35 signals lingering weakness, all amid a **30‑day volatility of 35.8%**. While the pipeline receives strong scientific attention, the combination of high valuation, bearish momentum, and sector‑specific risk suggests caution in the near term.